← 返回

BCMA 靶向 CAR-T 细胞疗法治疗复发和/或难治性多发性骨髓瘤:2023 ASCO 年会最新进展

英文原题:BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.

查看英文原题

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.

PubMed 2023/07/28(内容时间) J Hematol Oncol Q1 · IF 47.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

利用B细胞成熟抗原(BCMA)这一新型治疗靶点治疗复发和/或难治性多发性骨髓瘤(RRMM)已展现出惊人的结果,促使靶向BCMA的嵌合抗原受体(CAR)-T细胞疗法在RRMM中获得监管批准。目前已有两种获批的靶向BCMA的CAR-T 细胞疗法,全球研究人员正致力于在此基础上进一步改进靶向BCMA的疗法。我们讨论了促成CAR-T 获批的关键研究的长期数据、支持其在更早期治疗线中应用的3期试验,以及旨在缩短静脉到静脉时间的新型生产平台。我们重点介绍了2023年ASCO年会上的五篇关键摘要,这些摘要展示了靶向BCMA的CAR-T 细胞疗法在RRMM中的这些令人振奋的进展。

展开英文摘要原文

Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen (BCMA) has demonstrated incredible results, leading to regulatory approval of BCMA-targeted chimeric antigen receptor (CAR)-T cell therapies in RRMM. With now two approved BCMA-targeted CAR-T cell therapies, investigators globally are working to build off and improve upon BCMA-targeted therapies.

We discuss long-term data from the pivotal study that led to CAR-T approval, a phase 3 trial supporting their use in earlier lines, and novel manufacturing platforms to decrease vein-to-vein time.

We highlight five key abstracts from the 2023 ASCO Annual Meeting that showcase these exciting updates in BCMA-directed CAR-T cell therapies in RRMM.

论文信息

作者
Wu JF、Dhakal B
第一作者单位
Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.United States
通讯作者单位
BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, 9200 W Wisconsin Avenue, Milwaukee, WI, 53226, USA. bdhakal@mcw.edu.United States
文献类型
读者来信 · 美国 NIH 资助研究 · 非美国政府资助研究
期刊
Journal of hematology & oncology2023 Jul 28
原文标识
PubMed 37507805 · DOI 10.1186/s13045-023-01479-5